312 related articles for article (PubMed ID: 31699450)
21. Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs.
Zhao MY; Zhang W; Rao GW
Curr Med Chem; 2022 Aug; 29(29):5010-5040. PubMed ID: 35255783
[TBL] [Abstract][Full Text] [Related]
22. Janus kinases inhibitors for treating patients with rhupus.
Garufi C; Mancuso S; Spinelli FR; Truglia S; Ceccarelli F; Alessandri C; Conti F
Joint Bone Spine; 2020 Dec; 87(6):673-674. PubMed ID: 32534202
[No Abstract] [Full Text] [Related]
23. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
24. JAK inhibitors: Novel developments in management of ulcerative colitis.
Fiorino G; D'Amico F; Italia A; Gilardi D; Furfaro F; Danese S
Best Pract Res Clin Gastroenterol; 2018; 32-33():89-93. PubMed ID: 30060943
[TBL] [Abstract][Full Text] [Related]
25. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature.
Li H; Wang H; Qiao G; Liu Y; Zhang F; Pan F
Int Immunopharmacol; 2023 Sep; 122():110591. PubMed ID: 37441809
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
Jegatheeswaran J; Turk M; Pope JE
Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
[TBL] [Abstract][Full Text] [Related]
27. JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease.
Macaluso FS; RodrÃguez-Lago I
Curr Drug Metab; 2020; 21(4):247-255. PubMed ID: 32156234
[TBL] [Abstract][Full Text] [Related]
28. JAK Inhibitors: Prospects in Connective Tissue Diseases.
You H; Xu D; Zhao J; Li J; Wang Q; Tian X; Li M; Zeng X
Clin Rev Allergy Immunol; 2020 Dec; 59(3):334-351. PubMed ID: 32222877
[TBL] [Abstract][Full Text] [Related]
29. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
[TBL] [Abstract][Full Text] [Related]
30. Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.
Wang L; Ping X; Chen W; Xing W
Clin Rheumatol; 2021 May; 40(5):1725-1737. PubMed ID: 33067773
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation.
Koga T; Sato T; Umeda M; Fukui S; Horai Y; Kawashiri SY; Iwamoto N; Ichinose K; Nakamura H; Kawakami A
Clin Immunol; 2016 Dec; 173():147-148. PubMed ID: 27720846
[No Abstract] [Full Text] [Related]
32. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
Mogul A; Corsi K; McAuliffe L
Ann Pharmacother; 2019 Sep; 53(9):947-953. PubMed ID: 30907116
[No Abstract] [Full Text] [Related]
33. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis.
Rathore U; Thakare DR; Patro P; Agarwal V; Sharma A; Misra DP
Clin Rheumatol; 2022 Jan; 41(1):33-44. PubMed ID: 34729652
[TBL] [Abstract][Full Text] [Related]
34. Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention.
Colombel JF
Inflamm Bowel Dis; 2018 Sep; 24(10):2173-2182. PubMed ID: 29788127
[TBL] [Abstract][Full Text] [Related]
35. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of Janus Kinase inhibitor selectivity.
Choy EH
Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
[TBL] [Abstract][Full Text] [Related]
37. Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.
Kubo S; Nakayamada S; Tanaka Y
Expert Rev Clin Immunol; 2019 Jul; 15(7):693-700. PubMed ID: 30987474
[No Abstract] [Full Text] [Related]
38. How effective are JAK-inhibitors? Perspectives from clinical trials and real-world studies.
Lauper K; Hyrich KL
Expert Rev Clin Immunol; 2022 Mar; 18(3):207-220. PubMed ID: 34528855
[TBL] [Abstract][Full Text] [Related]
39. Janus kinase inhibitors for rheumatoid arthritis.
Yamaoka K
Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
[TBL] [Abstract][Full Text] [Related]
40. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
D'Amico F; Fiorino G; Furfaro F; Allocca M; Danese S
Expert Opin Investig Drugs; 2018 Jul; 27(7):595-599. PubMed ID: 29938545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
